Perioperative immunotherapy for NSCLC: Perspectives from an oncologist and a surgeon

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Mar 31 / Springer Healthcare

Perioperative immunotherapy for NSCLC: Perspectives from an oncologist and a surgeon

Oncology Cancer Immunotherapy Lung Cancer ELCC-2022

Description

Martin Reck and Hans Hoffmann discuss the optimal clinical trial endpoints and patient selection for neoadjuvant and adjuvant immunotherapy for resectable non-small-cell lung cancer.

Follow us here

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.